A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: JS001，an engineered anti-PD-1 antibody|DRUG: Nab-Paclitaxel|DRUG: Placebo
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.